The Phase 1b/2a study will assess the safety of CNP-103 in adults (aged 18-35) and pediatrics (aged 12-17) who have Stage III or newly diagnosed (within the last 6 months) T1D as well as C-peptide ...
CHICAGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- COUR Pharmaceuticals, a clinical-stage biotechnology company developing first-in-class, disease-modifying therapies designed to induce antigen-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback